Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00264576 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults
A Phase 2 study, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 2
- Development phase
- 613
- Enrollment target
NCT00264576: Completed Phase 2 study, sponsored by Novartis Vaccines.
NCT00264576 is a Phase 2 study that has completed, run by Novartis Vaccines. The registered enrollment target is 613 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (361% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00264576, a Phase 2 study, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 613 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of cell culture-derived, inactivated, subunit influenza vaccine in comparison to licensed Fluvirin vaccine administered to healthy adults ages 18 \< 50 years.
Primary Outcome
Non-inferiority was measured by the ratio of postvaccination geometric mean titers (cTIV vs. eTIV\_f) against all three vaccine strains as assessed by egg-derived antigen and cell-derived antigen haemagglutination inhibition (HI) assay.
Interventions
- BIOLOGICAL Influenza Virus Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 613 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
What the finished NCT00264576 record still lists
NCT00264576 is an interventional study that assigns participants to a tested intervention. The registered 613 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (361% higher).
The record links to 0 conditions, and to 1 intervention - of which Influenza Virus Vaccine is the first listed.
NCT00264576 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00264576 about?
NCT00264576 is a clinical study titled "Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults". The purpose of this study is to evaluate the safety and immunogenicity of cell culture-derived, inactivated, subunit influenza vaccine in comparison to licensed Fluvirin vaccine administered to healthy adults ages 18 \< 50 years.
What is the current status of trial NCT00264576?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 613 participants. The study started on 2005-10. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00264576?
The interventions under investigation include: Influenza Virus Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00264576?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00264576's enrollment target sits among peer trials
613 53rd of 2000 higher than 1,948 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01810913 · 613 participants · Phase 2
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
- NCT03821857 · 614 participants · Phase 4
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
- NCT05006716 · 614 participants · Phase 1
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- NCT06170788 · 614 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia